Evotec (ETR:EVT) received a €16.00 ($19.05) target price from investment analysts at Berenberg Bank in a note issued to investors on Thursday. The firm currently has a “neutral” rating on the stock. Berenberg Bank’s price target would suggest a potential upside of 35.65% from the company’s current price.
Several other equities analysts have also recently commented on the stock. Deutsche Bank set a €17.00 ($20.24) target price on shares of Evotec and gave the stock a “buy” rating in a research report on Tuesday. Oddo Bhf set a €20.00 ($23.81) target price on shares of Evotec and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Finally, Oddo Securities set a €14.00 ($16.67) target price on shares of Evotec and gave the stock a “neutral” rating in a research report on Friday, August 11th.
Evotec (EVT) opened at €11.80 ($14.04) on Thursday. Evotec has a 1 year low of €5.93 ($7.06) and a 1 year high of €22.50 ($26.79).
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.